Invuity (IVTY) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of Invuity (NASDAQ:IVTY) from a sell rating to a hold rating in a research note issued to investors on Wednesday.

A number of other research analysts also recently issued reports on IVTY. Zacks Investment Research raised shares of Invuity from a hold rating to a buy rating and set a $4.25 price objective on the stock in a research report on Thursday, July 5th. Stifel Nicolaus downgraded shares of Invuity from a buy rating to a hold rating in a research report on Tuesday, September 11th. Piper Jaffray Companies downgraded shares of Invuity from an overweight rating to a neutral rating in a research report on Tuesday, September 11th. Finally, William Blair downgraded shares of Invuity from an outperform rating to a market perform rating in a research report on Tuesday, September 11th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $6.81.

Shares of NASDAQ IVTY opened at $7.35 on Wednesday. The company has a current ratio of 2.13, a quick ratio of 1.69 and a debt-to-equity ratio of 10.57. Invuity has a 52 week low of $2.35 and a 52 week high of $9.55. The firm has a market capitalization of $177.54 million, a P/E ratio of -3.34 and a beta of 0.14.

Invuity (NASDAQ:IVTY) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.10. Invuity had a negative net margin of 89.29% and a negative return on equity of 837.22%. The company had revenue of $10.50 million for the quarter, compared to the consensus estimate of $10.73 million. analysts anticipate that Invuity will post -1.41 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Spark Investment Management LLC increased its position in Invuity by 138.2% during the 2nd quarter. Spark Investment Management LLC now owns 45,500 shares of the medical instruments supplier’s stock valued at $177,000 after purchasing an additional 26,400 shares during the period. JPMorgan Chase & Co. increased its position in Invuity by 5,196.9% during the 1st quarter. JPMorgan Chase & Co. now owns 47,672 shares of the medical instruments supplier’s stock valued at $184,000 after purchasing an additional 46,772 shares during the period. BlackRock Inc. increased its position in Invuity by 43.4% during the 2nd quarter. BlackRock Inc. now owns 56,511 shares of the medical instruments supplier’s stock valued at $221,000 after purchasing an additional 17,091 shares during the period. CVI Holdings LLC purchased a new position in Invuity during the 1st quarter valued at $302,000. Finally, Wells Fargo & Company MN increased its position in Invuity by 25.3% during the 1st quarter. Wells Fargo & Company MN now owns 80,451 shares of the medical instruments supplier’s stock valued at $310,000 after purchasing an additional 16,253 shares during the period. 59.95% of the stock is currently owned by institutional investors and hedge funds.

Invuity Company Profile

Invuity, Inc, a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities.

Read More: NASDAQ Stock Market Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply